Aerie Pharmaceuticals Logo

News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 21, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021 , Vicente Anido , PhD.
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 20, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease
AR-15512 (0.003%) BID Advancing to Phase 3; No Treatment-Related Serious or Systemic Adverse Events Reported Conference Call and Webcast Today, September 15 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Sep. 15, 2021-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 13, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 7, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Michael Bradley, Senior Director, Manufacturing
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 7, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 12, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Second Quarter 2021 Net Revenues of $27.2 Million Increased 50.8% over Second Quarter   2020 Second Quarter 2021 Net Revenue Per Bottle of $89 , up 14.7% over Second Quarter 2020 Phase 2b Topline Results for AR-15512 (COMET-1) Expected in the Third Quarter of 2021 Conference Call and Webcast Today,
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 28, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 20, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
TOP